Abstract
Objective
Activity planning for 90Y radioembolization aims to maximize the effect of the treatment while keeping toxicity acceptably low. Our aim was to describe the amount of residual activity in post-treatment v-vials and tubing and analyze the possible factors affecting it (total activity administered, number of split activity injection(s), previous treatments, administration artery and microcatheter size), as these may influence dosimetric planning and treatment.
Methods
This was a retrospective review using case records of patients who received 90Y-radioembolization for hepatic tumors at a single tertiary center. From August 2013 to September 2015, seventy-seven out of one hundred and fifty patients who received radioembolization with 90Y resin microspheres due to inoperable Hepatocellular Carcinoma (HCC) or liver metastases were included. The rest were mainly excluded due to incomplete data sets. The number of split activities (injections) for the radioembolization could be: one single injection, two or three. The remnant activity in post-treatment v-vials and tubing were measured for every patient. The administration arteries evaluated were: proper hepatic artery (PHA), right hepatic artery (RHA), middle hepatic artery (MHA), left hepatic artery (LHA) and small caliber branch arteries. The sizes of the microcatheters (2.2 or 2.7 Fr) used to administer the dose were also evaluated.
Results
In total, 77 out of 150 patients were included in the final analysis. There were 59 men of median age 64.0 years old. The total median dose loss was 0.10 GBq. The total dose loss increased 0.244 GBq [95 % CI = (0.169, 0.318)] when three split activities were given compared to single activity injection. Activity loss for each injection increased 0.0297 GBq [95 % CI = (0.0151, 0.0443)] for every 1.0 GBq increase of split activity injection. There were no significant statistical differences in the rest of patient characteristics.
Conclusions
There is significant loss of activity observed during radioembolization, which can have a major dosimetric impact. The total administered activity and the number of split injections during radioembolization are the main influencing factors. Further prospective studies as well as measures of clinical outcome are warranted.
This is a preview of subscription content, log in via an institution to check access.
References
Takahashi A, Himuro K, Yamashita Y, Komiya I, Baba S, Sasaki M. Monte carlo simulation of PET and SPECT imaging of 90Y. Med Phys. 2015;42:1926–35.
Selwyn R, Nickles R, Thomadsen B, DeWerd L, Micka J. A new internal pair production branching ratio of 90 Y: the development of a non-destructive assay for 90 Y and 90 sr. Appl Radiat Isot. 2007;65:318–27.
Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58:2188–97.
Ahmadzadehfar H, Biersack H, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105–21.
Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210.
Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D, et al. Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging. 2008;35:2088–96.
Ahmadzadehfar H, Meyer C, Pieper CC, Bundschuh R, Muckle M, Gartner F, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration. EJNMMI Res. 2015;5(54):015–0133 (epub 2015 Oct 13).
Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53:559–66.
Activity calculator for SIR-spheres microspheres available from http://apps01.sirtex.com/smac/. Accessed October 21.
Sirtex website. http://www.sirtex.com/us/clinicians/about-sirt/implant-procedure/. Accessed 18 Dec 2015.
Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical aspects of radioembolization with 90 Y microspheres. Tech Vasc Interv Radiol. 2007;10:12–29.
Smits ML, Elschot M, Sze DY, Kao YH, Nijsen JF, Iagaru AH, et al. Radioembolization dosimetry: the road ahead. Cardiovasc Intervent Radiol. 2015;38:261–9.
Kao YH, Magsombol BM, Toh Y, Tay KH, Chow PK, Goh AS, et al. Personalized predictive lung dosimetry by technetium-99 m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization. EJNMMI Res. 2014;4(33):014–0033 (eCollection 2014).
Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90 Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–500.
Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. J Gastrointest Oncol. 2015;6:134.
Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38:1393–406.
Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937–45.
Lau W, Kennedy AS, Kim YH, Lai HK, Lee R, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401–7.
Lam MG, Goris ML, Iagaru AH, Mittra ES, Louie JD, Sze DY. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. J Nucl Med. 2013;54:2055–61.
Ahmadzadehfar H, Haslerud T, Reichmann K, Meyer C, Habibi E, Fimmers R, et al. Residual activity after radioembolization of liver tumours with 90Y resin microspheres. Nuklearmedizin. 2014;53:95–8.
Pasciak AS, Ford J. comparing an antireflux catheter to standard end-hole catheter for Y90 treatment of HCC: an interview with alexander pasciak, PhD. Intervent Oncol 360. 2015;3(6):E60–2.
Liu C, Lin K, Lee R, Tseng H, Wang L, Huang P, et al. Model-based radiation dose correction for yttrium-90 microsphere treatment of liver tumors with central necrosis. Int J Radiat Oncol Biol Phys. 2011;81:660–8.
Acknowledgments
The first author would like to thank Fundación Bancaria Caja Navarra (“Becas a la excelencia de la Fundación Bancaria Caja Navarra”) and the Department of Health, Government of Navarra (“Beca para la Formación Continuada en Ciencias de la Salud”), for the grants that in part allowed fellowship funding support at the Singapore General Hospital.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interests.
Rights and permissions
About this article
Cite this article
Rodríguez, L.S., Thang, S.P., Li, H. et al. A descriptive analysis of remnant activity during 90Y resin microspheres radioembolization of hepatic tumors: technical factors and dosimetric implications. Ann Nucl Med 30, 255–261 (2016). https://doi.org/10.1007/s12149-015-1052-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-015-1052-9